Healthcare
ByBig Pharma Accelerates Shift to Off-the-Shelf Cell Therapy with Strategic Acquisitions
The global biopharmaceutical industry is entering a new phase in cell therapy innovation, marked by significant investments in…
Drugmakers Use AI to Speed Trials and Regulatory Filings
Pharmaceutical companies are increasingly using artificial intelligence to streamline clinical trials and regulatory filings. While AI has not…
AI Is Reshaping Pharma’s Economics—But Discovery Isn’t the Immediate Win
Executive Summary Artificial intelligence has moved from experimental promise to operational backbone across global biopharma. Industry leaders including…
Can Takeda’s $1.7 Billion Iambic Deal Redefine AI-Driven Small-Molecule Drug Discovery?
Executive Summary In a landmark AI-biopharma transaction, Takeda Pharmaceutical Co Ltd has entered a multi-year collaboration valued at…
Is CMS’s Block on Elevance MA Sign‑Ups a Turning Point for Payer Compliance?
The Centers for Medicare & Medicaid Services (CMS) has halted new Medicare Advantage enrollments for Elevance Health, freezing sign‑ups for…
Is Pierre Fabre’s US Cell‑Therapy Comeback Bid a Signal of Regulatory Reset for Rare Diseases?
Pierre Fabre is reviving its US cell‑therapy ambitions, seeking FDA re‑approval for Ebvallo after the agency initially rejected its submission.…
